PAVmed Inc. 10-K — AI Bull & Bear Analysis

The 10-K reveals a company at a critical inflection point, balancing high-convexity upside against severe liquidity risks. The transition to an asset-light model and the securing of the VA contract provide a credible blueprint for a turnaround. However, the 'going concern' warning from auditors cannot be ignored, as the company's survival depends on its ability to either secure further equity or trigger the commercial success of its subsidiaries rapidly. Ultimately, the investment thesis rests on whether the commercial catalysts for EsoGuard and the equity leverage in Veris can materialize before the company's limited cash runway expires. The massive tax asset fortress provides a long-term profit multiplier, but only if the company can first bridge the gap to profitability without completely eroding common shareholder value through further dilution.